TARE + Durvalumab + Bevacizumab for Liver Cancer (EMERALD-Y90 Trial)

Phase 2

Recruiting

Research Sponsored by AstraZeneca

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up time from first documented response until documented progression (approximately 3 years)

Awards & highlights

No Placebo-Only Group

Summary

"This trial aims to see how well a combination of durvalumab and bevacizumab given through an IV works in participants with liver cancer that cannot be removed through surgery, and who have

Who is the study for?

This trial is for adults with unresectable liver cancer (HCC) who can undergo TARE, have a Child-Pugh score class A (indicating good liver function), no cancer outside the liver, at least one measurable tumor in the liver, and are generally in good health or only mildly ill. They must also meet specific criteria for lung safety during treatment and have enough healthy liver tissue.

What is being tested?

The study tests if combining Durvalumab (an IV drug) and Bevacizumab (another IV drug) after Transarterial Radioembolization (TARE using Yttrium 90 microspheres) improves outcomes for patients with HCC that cannot be surgically removed. The effectiveness and safety of this combination therapy are being evaluated.

What are the potential side effects?

Potential side effects include those related to Durvalumab such as immune-related reactions affecting various organs, infusion reactions, fatigue; Bevacizumab may cause bleeding, high blood pressure; TARE could lead to abdominal pain or fever post-procedure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ time from first documented response until documented progression (approximately 3 years)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~time from first documented response until documented progression (approximately 3 years)

This trial's timeline: 3 weeks for screening, Varies for treatment, and time from first documented response until documented progression (approximately 3 years) for reporting.